CA2478165A1 — Sulfatase inhibiting progestogen-only contraceptive regimens
Assigned to Janssen Pharmaceutica NV · Expires 2003-09-25 · 23y expired
What this patent protects
A method of contraception is disclosed comprising the step of administering to a menstruating female a cycle of contraceptive therapy, said cycle of therap y including the continuous administration for the length of the cycle of a potent sulfatase inhibiting progestogen in a cont…
USPTO Abstract
A method of contraception is disclosed comprising the step of administering to a menstruating female a cycle of contraceptive therapy, said cycle of therap y including the continuous administration for the length of the cycle of a potent sulfatase inhibiting progestogen in a contraceptively effective and breast protecting dose, in the absence of the administration of an estrogen.
Drugs covered by this patent
- Estrace (ESTRADIOL) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.